A closer look at Eleven Bio's Q2 results

|About: Eleven Biotherapeutics... (EBIO)|By:, SA News Editor

Eleven Biotherapeutics (EBIO) Q2 results: Revenues: $0.8M (+276.7%); Operating Expenses: $8.8M (+145.6%); Net Loss: ($8.1M) (-78.4%); Loss Per Share: ($0.51) (+85.2%); Quick Assets: $45.0M (+467.0%).

No financial guidance given.